Overview

Phase II Trial Evaluating the Safety and Efficacy of the Combination of Zimberelimab, Domvanalimab and Sacituzumab Govitecan as 1L Therapy for PD-L1 Positive Advanced TNBC

Status:
NOT_YET_RECRUITING

Trial end date:
2028-12-28

Target enrollment:

Participant gender:

Summary

The ADJUNCT is a single-arm, phase II clinical trial to evaluate the safety and efficacy of the combination of zimberelimab, domvanalimab and sacituzumab govitecan as first-line therapy for patients with PD-L1 positive advanced or metastatic triple-negative breast cancer.

Phase:

PHASE2

Details

Lead Sponsor:

MedSIR

Treatments:

sacituzumab govitecan
zimberelimab